Beatrice Setnik - Concepedia

Author

Beatrice Setnik

Pfizer (United States)

Also Known As

B. Setnik, Beatrice S. Setnik, Beatrice Setnik, Beatrice Setnik, PhD

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of Toronto Duke Medical Center Syneos Health (United States)Eisai (United States)

About

Beatrice Setnik is an author at Pfizer (United States) specializing in pharmacology, medicine, and substance abuse.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	175
2	Health Sciences	3	3	154
3	Social Sciences	1	1	21
4	Anesthesia	1	1	53
5	Emergency Medicine	1	1	72

Beatrice Setnik

Publications

993

Citations

H-Index

Page 1

	Year	Citations
Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy Beatrice Setnik, Michael McDonnell, Catherine Mills, SLEEP	2019	187
Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial Kerri A. Schoedel, Isabella Szeto, Beatrice Setnik, Epilepsy & Behavior	2018	164
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations Sandra D. Comer, James P. Zacny, Robert H. Dworkin, Pain Opioid EpidemicSubstance UseDrug AssessmentAddiction MedicinePain Management	2012	72
Subjective Effects and Safety of Whole and Tampered Morphine Sulfate and Naltrexone Hydrochloride (ALO-01) Extended-Release Capsules versus Morphine Solution and Placebo in Experienced Non-Dependent Opioid Users Joseph Stauffer, Beatrice Setnik, Marta Sokolowska, Clinical Drug Investigation Opioid EpidemicPain MedicineSubjective EffectsPharmacotherapyAddiction Medicine	2009	53
Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting James A. Brown, Beatrice Setnik, Keung Lee, Journal of Opioid Management	2017	51
Impact of Intravenous Naltrexone on Intravenous Morphine-Induced High, Drug Liking, and Euphoric Effects in Experienced, Nondependent Male Opioid Users Lynn R. Webster, Franklin K. Johnson, Joseph Stauffer, Drugs in R&D	2011	43
The Abuse Potential of Remoxy<sup>®</sup>, an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone Beatrice Setnik, Carl L. Roland, Jody M. Cleveland, Pain Medicine	2011	41
Ethanol effects on drug release from Verapamil Meltrex®, an innovative melt extruded formulation Wyatt J. Roth, Beatrice Setnik, M. Zietsch, International Journal of Pharmaceutics Pharmaceutical ScienceEthanol EffectsPharmaceutical TechnologyVerapamil Meltrex®Pharmacology	2008	41
Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression<b>:</b>A randomized, double‐blind, placebo‐controlled trial Eugene R. Viscusi, Marc C. Torjman, Catherine Munera, Clinical and Translational Science	2021	32
A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment Richard Rauck, M. Hale, Almasa Bass, Pain Pain TherapyPain MedicineTitration PeriodRandomized Double-blindPharmacotherapy	2015	29

Page 1